Departing from traditional reliance on clinical symptomatology, they advocated for a biomarker-based schema, known as the AT(N) system, classifies AD according to the presence of key pathophysiological markers: amyloid-beta (Aβ, A), tau (T), and neurodegeneration (N). Here, MAPT is linked to Alzheimer disease.